⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BHVN News
Biohaven Ltd.
Belhaven Announces Significant Expansion of Nasdepi Patent Portfolio, Commercial Supply Readiness, and FDA Alignment on Key Topics
accessnewswire.com
BHVN
Bexorg Expands Leadership Team with Appointments of Bruce Car, Ph.D., as Chief Scientific Officer and Michael Fenn, Ph.D., as Chief Business Officer
globenewswire.com
BHVN
AGIO
Form 8-K
sec.gov
BHVN
Biohaven Announces Scientific Leadership Transitions
prnewswire.com
BHVN
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
prnewswire.com
BHVN
IgA Nephropathy Clinical Trial Space Intensifies with 25+ Companies in Active Development | DelveInsight
globenewswire.com
NVS
VRTX
BIIB
VTRS
AZN
IONS
TAK
ARWR
BHVN
NVO
LLY
LXRX
XRTX
REGN
FMS
MDT
AMPH
DRCT
BMRC
MAZE
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
prnewswire.com
BHVN
Form 8-K
sec.gov
BHVN
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
prnewswire.com
BHVN
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
prnewswire.com
BHVN